Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cachexia: full-pipeline trial registry
3 of 17 indexed Cachexia trials are currently recruiting.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 3 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Cachexia: 17 US clinical trials tracked, 3 recruiting.
Cachexia is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 3 of these trials.
Enrollment posture brief
Registry condition cachexia
OPEN 3 | RECR 18% | LATE 8 | EARLY 7 | RANK #1004 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Malignant Neoplasm (18% recruiting · 17 trials)
Cachexia lists 3 open slots (18% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cachexia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cachexia is recruiting below its size-band peers.
3 of 17 indexed trials (17.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cachexia research.
Bristol-Myers Squibb accounts for 3 of 17 trials (17.6%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Cachexia trials plan to enrol fewer than 100 people.
Median target enrolment is 67 among the 14 trials that report a genuine target (sentinel values excluded). 9 of those (64.3%) plan for fewer than 100 participants.
-
Cachexia research is mostly interventional.
16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
NCT06989437
Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
Wake Forest University Health Sciences
NCT05376592
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
AVEO Pharmaceuticals
NCT05865535
Ruxolitinib for Cancer Cachexia
Tu Dan
NCT04906746
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Helsinn Therapeutics (U.S.)
NCT01387282
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
Radiation Therapy Oncology Group
NCT00053053
Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
Norwegian University of Science and Technology
NCT02330926
Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT03359473
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Alliance for Clinical Trials in Oncology
NCT00040885
Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women
Charles Drew University of Medicine and Science
NCT00004400
The Safety and Effectiveness of Megace in HIV-Infected Women
Bristol-Myers Squibb
NCT00002345
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
Wake Forest University Health Sciences
NCT00031785
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Pfizer
NCT04803305
Bovine Lactoferrin Supplement in Improving Taste in Patients With Cancer Receiving Chemotherapy
Wake Forest University Health Sciences
NCT01941810
A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
Bristol-Myers Squibb
NCT00002067
A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition
Bristol-Myers Squibb
NCT00002300
Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer
Mayo Clinic
NCT00046904
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cachexia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cachexia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cachexia page
17 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Cachexia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Cachexia trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cachexia condition card totals 17 registered trials; most-linked intervention Megestrol acetate; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.